The Brigham and Women's PGY2 Infectious Diseases Pharmacy Residency is recruiting for the 2026-27 year! Scan the second QR code below to schedule an on-demand meeting with program leadership and current residents

Three new UTI antibiotics active vs. ESBL organisms have been approved by the FDA in the past year alone! Which will make it to market first: pivmecillinam, sulopenem-probenecid, or gepotidacin? #IDsky

The aztreonam-avibactam (Emblaveo) FDA approval Friday flew wayyyy under the radar without the normal FDA alerts or AMDAC review. But AbbVie has the press release (news.abbvie.com/2025-02-07-U...) and the FDA package insert is now available! www.accessdata.fda.gov/drugsatfda_d...

🆕💫 Narrative Review @cmicomms.bsky.social @jeffpears0n.bsky.social Tetracyclines, the Old and the New 🔹Tetracycline 1953 ✨Doxycycline 1967 🔹Minocycline 1971 🔹Tigecycline 2005 🔹Eravacycline 2018 🔹Omadacycline 2018 #IDsky #EMIMCC www.sciencedirect.com/science/arti...

Great to see the CACTUS study in print! authors.elsevier.com/c/1kHGc5E-Uo... Ceftaz-avi vs. Ceftol-tazo for MDR Pseudomonas. Tremendous effort by all involved, and thanks to a great leadership team. The PRECEDENT network is cooking up much more, check it out at www.precedentnetwork.com! #IDsky

I'm excited to join the #IDSky 🦋 community! What better way to start than with our study that flew under the radar last month integrating vancomycin AUC monitoring in OPAT, which saw HUGE drops in AKI rates (23% to 6% overall). Safe to say AUC is here to stay! academic.oup.com/ofid/article...

Thank you @IDSAInfo for this honor! I'm humbled to become a fellow of IDSA, especially being just 1 of 8 PharmDs recognized with #FIDSA this year. I can't wait to see everyone in LA in October at @IDWeekmtg! #WeAreID

Concomitant carbapenem & valproate use is THE most relevant drug interaction I teach residents & students about. In our review, seizures occured in 46% of encounters😱. Avoid this combination at all costs in patients using valproate for seizure control!

Alright #IDTwitter, what would you recommend in the situation below? Source control unattainable, infected graft so hoping for short-term acute treatment and long-term suppression. NDM positive Providencia rettgeri

Our new study evaluating gentamicin dosing strategies for endocarditis was published in @jac_amr! We saw HUGE rates of nephrotoxicity (~50%) in the divided dosing group. Next research question from our MGB group - time to ditch gent altogether?

Catching up on podcasts today, I had the best random back-to-back listening experience! Looking at the pip-tazo breakpoints from two different angles, great discussion in both from @SIDPharm and @ASMicrobiology & #IDTwitter

The tixagevimab-cilgavimab (Evusheld) EUA was revoked today by the FDA, marking the end of these #COVID Mab posts from me for the foreseeable future. #IDtwitter

ASPE/HHS published a breakdown of oral #COVID19 treatment utilization by state last week - Paxlovid vs. molnupiravir. As I expected, Massachusetts is on the far end of the spectrum favoring Paxlovid... #IDTwitter 1/2

The @US_FDA officially withdrew bebtelovimab's EUA this week as variant resistance has surpassed 65%, following in the steps of many #COVID Mabs before it. The only Mab left standing (barely) is Evusheld (79% resistant, but no alternatives) #IDTwitter

I also have joined med Mastodon and will likely be moving over to that platform gradually in the coming weeks, come along for the ride! #medmastodon #IDmastodon #IDTwitter

I missed last Friday's Tweet, so I added some extra insight in this post. Updated Mab variant table, with expected susceptibility against circulating variants in the second image (per ). We shut down bebtelovimab last week at BWH #IDTwitter #COVID19

While not much has changed on my Mab table since the last post, a whole lot has changed with the current #COVID variants. We're now looking at ~27% resistance to bebtelovimab and ~50% resistance to Evusheld. Stay tuned for updates from @NIHCOVIDTxGuide

This may need to be a weekly Tweet based on how quickly the #COVID19 Omicron variants are changing. Below is the updated COVID Mabs table, and just as importantly the variant situation right now in the US. Note the variants quickly rising to the top of the list... #IDTwitter

Omicron continues its never-ending variant kick! BA.4.6 & BA.2.75 are added below. This will be my last variant table that is all-inconclusive. In order to make more readable going forward it will just be with active(ish) variants and #COVID Mabs #IDTwitter

Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂

Just in time for the holiday weekend, the FDA authorized re-dosing of Evusheld every 6 months! They also snuck in neutralizing data for BA.4/5, so time for another table update! AstraZeneca says 33-65-fold reduction is OK, what say you? #COVID #IDTwitter

The bebtelovimab fact sheet was updated last week with info on BA.2.12.1, BA.4, and BA.5 (), which means it's time for an update to the #COVID variant table! #IDTwitter

This flew under the radar (even for me as an author!), but the @BrighamWomens team recently had an excellent (succinct) sepsis review paper published - we discuss time to abx in sepsis v. septic shock, prolonged vs. push 1st dose, order of admin, and more!

Oh how far we've come! I remember presenting a clinical pearl on Shingrix use in the immunocompromised in early 2018 with no published efficacy data, and now we have plenty! @AnnMarieI3 #MASHP22

This was an absolutely outstanding keynote at #MASHP22, thank you @OjikutuBisola!

Out with the old, in with the new! The 2022 ACIP pneumococcal vaccination updates should simplify administration quite a bit. Thanks @AnnMarieI3 for the vaccine update and visuals at #MASHP22!

Question for #IDTwitter, which would you rather? Uncontrolled intra-abdominal source with MDR Citrobacter freundii and PsA aeruginosa. Are you worried less about ceftaz-avi at breakpoint for PsA or ceftol-tazo and inducible ampC with citrobacter? Poll in next Tweet! @BWDionne

Another #COVID Mab Update! Rec for Evusheld now double the dose (already causing local logistical nightmares) based on Omicron activity (see table below) and safety from failed TACKLE treatment study, but no clinical efficacy data

You knew it would come on a Friday night! Bebtolivimab received EUA (based on only limited Phase 2 data but promising variant data). Time for a variant table update - more to come on BA1.1 and BA.2 #COVID19

Show me your inpatient COVID waves without showing me your inpatient COVID waves...#IDTwitter #COVID19 #remdesivir

Shifting an entire hospital's COVID Mab response for treatment, PEP, and PrEP, Paxlovid, and now remdesivir PINETREE data in full! What. A. Day.

Annndd boom goes the dynamite🧨- Nirmatrelvir/r (Paxlovid) received EUA minutes ago! #IDTwitter #COVID19

Here's the updated COVID variant table, with a thread on the (limited) data behind the updates!

With the arrival of omicron, it was time to update our COVID Mab efficacy against variants table! #IDTwitter #COVID19 #weneedmoredata

Bamlanivimab-etesevimab is back! At least in Massachusetts and 21 other states. Probably the only good thing that has come out of the Delta variant...#COVID19

The new @CDCgov STI guidelines have been published! Updated tx recs for gonorrhea, chlamydia, trichomoniasis, and PID, along with many additional updates in STI testing & vaccination #IDTwitter

Looking for a quick podcast on current COVID-19 treatment considerations and controversies? @PaulSzumita and I’ve got you covered! #COVID19 @ASHPOfficial

With the tocilizumab RECOVERY pre-print out, many have asked if I'd be updating my summary slide. Well here it is, spurred on by you all, oh and another presentation tomorrow @BrighamWomens *caveat: mortality was not primary outcome in many of these studies* #COVID19 #IDTwitter

Summarizing all of the tocilizumab data for #COVID19 in one slide is basically impossible, but here is my attempt from the debate today, in order of publication/pre-print date *caveat: mortality was not primary outcome in many of these studies* #IDTwitter

When we learned of ceftol-tazo recall on Monday (h/t @ErinMcCreary on deets a day later), we had to adjust regimens for multiple pts. Two had DTR Pseudomonas, both ceftaz-avi-R w/ susceptibilities in 2nd tweet below. Day 3 of VAP treatment, what would you switch to?

Exactly a week after the Pfizer-BioNTech vaccine data release, we now have Moderna's info! FDA briefing doc: , Moderna briefing doc: , meeting on Thurs 12/17 again open to all on Youtube () or Twitter (@US_FDA)

The Pfizer vaccine data has officially been released! Link to FDA briefing doc: , link to Pfizer briefing doc: . Meeting on Thursday is open to all, available on Youtube () and Twitter (@US_FDA)! #IDTwitter

Doesn't the FDA know that I have 7+ hours of meetings already scheduled for today and just cannot handle another EUA on a Friday??? #EUA #baricitinib

What a great visual demonstrating the flaws of using ECOFF values to set breakpoints #SIDP2020

Some excellent take-aways from @geschena on the use of antifungals empirically in the ICU #SIDP2020

Risk factors for invasive candidiasis - they're ubiquitous in our ICU populations @geschena #SIDP2020

Giving a talk on remdesivir's FDA approval tonight, and couldn't resist attempting to put the whirlwind that has been the past 8 months into one slide. I call it the Remdesivir Rollercoaster 🎢 #remdesivir in #COVID19

The #COVID19 Real Time Learning Network is now live! With the latest clinical guidance, including therapeutics & vaccines, clinical trials data, and resources all in 1 place with a crisp clean design h/t @IDSAInfo @HIVMA @PharmerMeg @Dr_Mike_Stevens et al!

In my deep re-review of the lit tonight for the therapeutics section of , I found this gem: from Feb 2020 re: steroids in #COVID19. Hindsight is 20-20, & expect big updates to the website in the coming weeks! @DrCLeeCohen #IDtwitter

Our case series on the use of omadacycline in Mycobacterium abscessus is out now in #OFID! Still lots of work to do in this area, but hopefully this provides some insight for folks on clinical use and summary of the data thus far #IDTwitter @IDSAInfo